The Progress and Development Prospects of Targeted Therapy for Pancreatic Carcinoma

Pancreatic cancer is a malignant tumor with extremely high malignancy and poor prognosis. At present, targeted therapy is the latest progress in the treatment of pancreatic cancer; The development of receptors for drugs targeting pancreatic cancer has also made great progress, and specific drugs targeting some receptors have also been approved for marketing. However, the clinical effect of targeted therapy for pancreatic cancer has not reached a stable state, and the side effects of some targeted drugs have not been effectively solved. This article reviews the research on therapeutic targets for pancreatic cancer such as TROP2, PI3K and CIP2A in recent years and the development of Claudin 18.2, a new target. It is found that the research on Trop2 and CAPA is relatively complete and has achieved effective results. Both of them are effective targets for targeted treatment of pancreatic cancer. However, the research on PI3K and Claudin 18.2 is less, and their effects and mechanisms are not effectively supported by theory. In addition, this article summarized the research on EGFR, Her, CAR-T, GRPR and other receptors related to targeted treatment of pancreatic cancer and their related drugs and therapies. It was found that the research on EGFR, Her and CAR-T had achieved significant research results in the clinical stage, and their related drugs and therapies were approved for marketing; However, there are still deficiencies in the research on the influencing factors, stable clinical efficacy, and side effects of drugs targeting the aforementioned receptors. Future research can focus on overcoming tumor microenvironment, avoiding side effects of targeted drugs for pancreatic cancer, and new targets for targeted treatment of pancreatic cancer.